Fetch faculty shares insight on new canine cancer treatment


In a dvm360® interview, Sue Ettinger, DVM, DACVIM (Oncology), highlights an innovative, effective method for treating mast cell tumors

During this dvm360® interview, Sue Ettinger, DVM, DACVIM (Oncology)—also known as "Dr Sue Cancer Vet"—describes the science behind Stelfonta (tigilanol tiglate injection), an alternative treatment to surgery for canine mast cell tumors. She excitedly divulges how a similar option is proving effective for other species, including humans.

A partial transcript of the interview is below. View the video for more of the discussion.

Sue Ettinger, DVM, DACVIM (Oncology): It's really exciting that [Stelfonta], this innovative brand new drug that just got FDA approved, in the end of 2020 . . . it's been available in clinic since February of 2021. But it's also being used to treat human cancers, and I think that's really exciting as well. In case you do mixed animal [medicine], there are a couple of case reports in using it for some of the cutaneous tumors in horses like sarcoids and melanoma.

Register for our Fetch dvm360® Conference in Kansas City conference from August 26-28 here.

Related Videos
Managing practice caseloads
Nontraditional jobs for veterinary technicians
Angela Elia, BS, LVT, CVT, VTS (ECC)
Honey bee
© 2024 MJH Life Sciences

All rights reserved.